Form 4 for MAIA MAIA Biotechnology, Inc.
Accepted 2023-02-17 00:00:00 ET · period of report 2023-02-15 · accession 0001127602-23-005727 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-02-17 | 2023-02-15+ | MAIA | Vitoc Vlad | CEO, Dir, 10% | P - Purchase | $4.25 | +20 | 793.5K | +0.0% | +$85 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-15 | P | A | 10 | $4.25 | 793,474 | D | — | — | (F1) The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Vitoc that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. |
| 2 | Common | Common Stock | 2023-02-16 | P | A | 10 | $4.25 | 793,484 | D | — | — | (F1) The purchases reported in this Form 4 were automatically effected pursuant to a previously executed purchasing plan for Mr. Vitoc that is intended to comply with Rule 10b5-1(c) promulgated under the Securities Exchange Act of 1934, as amended. |